Document Detail


Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs.
MedLine Citation:
PMID:  19013488     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A silica-lipid hybrid (SLH) microcapsule system for oral delivery of poorly water-soluble drugs is reported for the first time. For the model drug celecoxib (CEL), SLH microcapsules composed of medium-chain triglycerides, lecithin and silica nanoparticles; with an internal porous matrix structure, were shown to offer several physicochemical and biopharmaceutical advantages in comparison with unmodified drug, lipid emulsion, dry emulsion and the commercial product, Celebrex. DSC and XRD analyses confirmed non-crystalline CEL in SLH microcapsules and verified medium term physical stability. Dissolution under sink conditions revealed a 2- to 5-fold increase in dissolution efficiencies (%DE) and significantly reduced t(50%) (> or =50-fold) for CEL formulated as SLH microcapsules. Orally dosed in vivo studies in rats demonstrated superior pharmacokinetics for SLH microcapsules. Specifically, the fasted-state bioavailability (F) was statistically higher (p<0.05) than for aqueous suspension, lipid solution, o/w emulsion and a maltodextrin-stabilised dry emulsion, and was greater than for Celebrex. SLHs showed the highest maximum plasma concentration (C(max)) among all tested formulations (p<0.05). Linear correlations were observed between %DE and the pharmacokinetic parameters (F and C(max)). It is postulated that SLH microcapsules improve CEL oral absorption via dissolution enhancement, potentially in conjunction with other unexplored mechanisms, hence offering the possibility of dose reduction for improved therapeutic efficacy and cost-effectiveness of poorly soluble drugs.
Authors:
Angel Tan; Spomenka Simovic; Andrew K Davey; Thomas Rades; Clive A Prestidge
Related Documents :
9876608 - Preparation, characterization, and dissolution studies of ibuprofen solid dispersions u...
19040178 - Preparation and evaluation of self-microemulsifying drug delivery system containing vin...
17729098 - Solid carriers for improved solubility of glipizide in osmotically controlled oral drug...
20172678 - Study on similar traditional chinese medicines cornu cervi pantotrichum, cornu cervi an...
11201158 - Progress and problems in the prescribing/dispensing split and "divided package sales" b...
24007328 - A physiologically-based flow network model for hepatic drug elimination i: regular latt...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-10-30
Journal Detail:
Title:  Journal of controlled release : official journal of the Controlled Release Society     Volume:  134     ISSN:  1873-4995     ISO Abbreviation:  J Control Release     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-02-09     Completed Date:  2009-04-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607908     Medline TA:  J Control Release     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  62-70     Citation Subset:  IM    
Affiliation:
Ian Wark Research Institute, ARC Special Research Centre for Particle and Material Interfaces, University of South Australia, Mawson Lakes, SA 5095, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Biological Availability
Capsules / chemistry*,  pharmacokinetics*
Drug Delivery Systems / methods*
Lipids / chemistry
Male
Pyrazoles / administration & dosage,  chemistry,  pharmacokinetics*
Rats
Rats, Sprague-Dawley
Silicon Dioxide / chemistry
Solubility
Sulfonamides / administration & dosage,  chemistry,  pharmacokinetics*
Chemical
Reg. No./Substance:
0/Capsules; 0/Lipids; 0/Pyrazoles; 0/Sulfonamides; 169590-42-5/celecoxib; 7631-86-9/Silicon Dioxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential role of alpha(v)beta(3) and alpha(v)beta(5) integrins in internalization and transducti...
Next Document:  Hypertensive activity of synthesized PTH(25-34) and Ac-PTH(25-30)-NH2 in rats.